Drug analysis: vericiguat

Drug analysis: vericiguat

  • December 2017 •
  • 14 pages •
  • Report ID: 5336352 •
  • Format: PDF
Drug Overview
Vericiguat is a first-in-class soluble guanylate cyclase (sGC) stimulator that acts to increase levels of cyclic guanosine monophosphate (cGMP) via the nitric oxide-sGC-cGMP pathway. In heart failure, there is reduced bioavailability of nitric oxide due to systemic inflammation and vascular dysfunction, resulting in a reduction in cGMP synthesis.

Disruption in the nitric oxide-sGC-cGMP pathway results in issues in the regulation of myocardial and renal function, thus resulting in increased potential for myocardial damage.